ClinicalTrials.gg
CompletedNCT01049334Updated Sep 21, 2017Results posted

A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis

A Phase 3 interventional study of Placebo and Flurbiprofen in Pharyngitis, sponsored by Reckitt Benckiser LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-21.

Sponsored by Reckitt Benckiser LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies in Pharyngitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pharyngitis · United States.

Enrollment
18th of 35
204 · median 204
Started
2009
with 3 others
Phase 3
18 of 41
none open now
Registered
13th of 41
by date
Lead sponsor
3 of 41
Reckitt Benckiser LLC

Among the 41 studies in Pharyngitis with a site in United States, this one is the 18th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2009, is one of 18 in phase 3, and was the 13th registered.

Pharyngitis

227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.

Browse Pharyngitis studies →

Open to participants now

4 of the 41 studies in Pharyngitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Pharyngitis studies recruiting now, 5 (26%) set no upper age limit and 10 (53%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Pharyngitis with a site in United States, or all of them as a file.
02

Study summary

The purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore throat due to acute pharyngitis.

03

Conditions studied

  • Pharyngitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has a complaint of sore throat.
  2. If the patient is a female of , she has been using effective since the last date of menses and is not breast-feeding or lactating.
  3. If the patient is a female of childbearing potential, the patient must have a negative urine pregnancy.
  4. The patient has provided written prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. The patient has a history of an upper gastrointestinal ulcer within the past 60 days, is currently experiencing upper gastrointestinal complaints, or is currently taking medication regularly (≥ three times in the previous week).
  2. The patient has a history of any hepatic disease or renal dysfunction.
  3. The patient has a history of chronic analgesic use (≥ three times per week over the prior four weeks). (Patients on low-dose aspirin therapy may be allowed in the study per investigator's clinical decision.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    flurbiprofen 8.75 mg lozenge

    Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.

    Drug: Flurbiprofen

  • Placebo comparator
    Placebo lozenge

    Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.

  • Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.

06

What researchers measure

Primary outcomes

  1. Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)

    STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time-weighted pain intensity differences from baseline until 24 hours. The full range was -114609 (complete pain relief within 2 minutes of dosing that lasts 24 hours) to 29191 (maximum pain within 2 minutes lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.

    Time frame: baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)

Secondary outcomes

  1. Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)

    STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dosing. The full range was -9405 (complete pain relief within 2 minutes of dosing that lasts 2 hours) to 2395 (maximum pain within 2 minutes lasting 2 hours) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.

    Time frame: baseline (pre-dose), 2 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2)

  2. Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline

    Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and 2 hours post dose. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9192 (no difficulty swallowing within 10 minutes of dosing that lasts 2 hours) to 2808 (maximum difficulty swallowing within 10 minutes lasting 2 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.

    Time frame: baseline (pre-dose), 2 hours post-dose (every 10 minutes until hour 2)

  3. Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline

    Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and until 24 hours post dose. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -110304 (no difficulty swallowing within 10 minutes of dosing that lasts 24 hours) to 33696 (maximum difficulty swallowing within 10 minutes lasting 24 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.

    Time frame: baseline (pre-dose), 24 hours post-dose (every 10 minutes until hour 2, every 30 minutes until hour 6, hourly from 7-24 hours)

  4. Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline

    The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9336 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2664 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS.

    Time frame: baseline (pre-dose), 2 hours post-dose (at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours)

  5. Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline

    The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and specified timeframes until 24 hours. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -112032 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31968 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS.

    Time frame: baseline (pre-dose), 24 hours post-dose (1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, 2 hours, 2½ hours, 3 hours, 3½ hours, 4 hours, 4½ hours, 5 hours, 5½ hours, and 6 hours after the first dose, hourly from 7-24 hours)

  6. Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8

    Tonsillo-Pharyngitis Assessment, or TPA, is an index of seven clinical features of the pain-producing condition itself, pharyngeal inflammation. The clinical features concern temperature, oropharyngeal color, size of tonsils, number of enanthems, largest size of cervical lymph node, number of lymph nodes, and maximum tenderness of lymph nodes. Each variable was rated on a scale of 0-3, with 0 representing the normal value, and 3 representing severe inflammation. The seven values are added together to create the TPA, ranging from 0-21. Negative change values represent improvement of symptoms.

    Time frame: Baseline (pre-dose), 24 hours post-dose

  7. Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose

    P.A.I.N is a four step scale in which physicians rate the severity of pharyngeal inflammation: No inflammation, mild, moderate and severe inflammation.

    Time frame: 24 hours post-dose

  8. Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose

    Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: "Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.

    Time frame: 24 hours

  9. Participant Satisfaction Scores 24 Hours After Initial Dose

    After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied.

    Time frame: 24 hours

  10. Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7)

    Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of the study by answering the following question: "Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.

    Time frame: Day 7

  11. Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe

    STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -116196 (no pain at any post-dose time (0) - average baseline) to 27804 (maximum possible pain (100) - average baseline). Participants with their last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation.

    Time frame: baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)

  12. Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose

    Participants used a 6-category relief scale (no relief to complete relief) to grade the relief of his/her throat pain. The patient was instructed to swallow and: "Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now."

    Time frame: 2 hours

  13. Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05

    Data reported in summary form in Primary Outcome #1 are reported here at each post-dose timepoint until the comparison resulted in a P-value \<=0.05 between the two treatment arms. STPIS was used to measure sore throat pain intensity using a 100-mm visual analog scale completed by participants that measures "pain on swallowing" (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. The full range of the scale varies by timepoint due to the time weighting sum of SPID. The full scale at 40 minutes post dose was -3188 (complete pain relief within 2 minutes of dosing that lasts 40 minutes) to 812 (maximum pain within 2 minutes lasting 40 minutes) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (rec

    Time frame: baseline (pre-dose), up to 23 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-23)

  14. Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement

    As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. An alternative definition of STPIS time to onset of relief was the time from initial dose to the time the participant reaching DIL for at least 30 minutes. Data were censored if DIL was not achieved by 120 minutes following initial dose. Definite improvement must also occur prior to re-dosing or using rescue medication.

    Time frame: 2 hours

  15. Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL)

    As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. The time of first achieving DIL for 30 minutes within 6 hours (or until rescue or re-dosing) post-dosing will be determined. And the time falling below DIL within 6 hours will be determined. Duration is then defined as the time from first DIL until falling below DIL. Duration was set to zero if the STPIS score does not reach the DIL for at least 30 minutes for STPIS during the 6 hours.

    Time frame: 6 hours

07

Results

Posted Sep 21, 2017

Participant flow

Participant flow — Overall Study
MilestoneFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Started102102
Completed9395
Not completed97
Withdrew: Withdrawal by subject53
Withdrew: Adverse event23
Withdrew: Physician decision20
Withdrew: Protocol violation01

Outcome measures

PrimaryTime Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)

STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time-weighted pain intensity differences from baseline until 24 hours. The full range was -114609 (complete pain relief within 2 minutes of dosing that lasts 24 hours) to 29191 (maximum pain within 2 minutes lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.

Time frame:
baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)
Reported as:
Least squares mean · units on a scale
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)-473.7 ± 45.4428-322.3 ± 45.6708
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0201 (The a priori threshold for statistical significance is 0.05. No adjustments for statistical multiplicity were required.) · Least-square means difference: -151.5 · 95% CI -278.9 to -24.0Treatment as a fixed effect and baseline STPIS as a covariate.
SecondaryTime Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)

STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dosing. The full range was -9405 (complete pain relief within 2 minutes of dosing that lasts 2 hours) to 2395 (maximum pain within 2 minutes lasting 2 hours) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.

Time frame:
baseline (pre-dose), 2 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2)
Reported as:
Mean · units on a scale
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)-43.4 ± 39.20-23.5 ± 29.52
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = <.0001 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.) · Least-square means difference: -19.6 · 95% CI -29.2 to -9.9Treatment as a fixed effect and baseline of the variable predicted as a covariate
SecondaryTime Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline

Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and 2 hours post dose. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9192 (no difficulty swallowing within 10 minutes of dosing that lasts 2 hours) to 2808 (maximum difficulty swallowing within 10 minutes lasting 2 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.

Time frame:
baseline (pre-dose), 2 hours post-dose (every 10 minutes until hour 2)
Reported as:
Mean · units on a scale
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline-39.1 ± 38.64-16.6 ± 29.34
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = <0.0001 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.) · Least-square means difference: -22.3 · 95% CI -31.7 to -12.9Treatment as a fixed effect and baseline of the variable predicted as a covariate
SecondaryTime Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline

Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and until 24 hours post dose. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -110304 (no difficulty swallowing within 10 minutes of dosing that lasts 24 hours) to 33696 (maximum difficulty swallowing within 10 minutes lasting 24 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.

Time frame:
baseline (pre-dose), 24 hours post-dose (every 10 minutes until hour 2, every 30 minutes until hour 6, hourly from 7-24 hours)
Reported as:
Mean · units on a scale
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline-460.8 ± 498.79-274.3 ± 455.35
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0071 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.) · Least-square means difference: -181.7 · 95% CI -313.7 to -50.0Treatment as a fixed effect and baseline of the variable predicted as a covariate
SecondaryTime Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline

The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9336 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2664 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS.

Time frame:
baseline (pre-dose), 2 hours post-dose (at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours)
Reported as:
Mean · units on a scale
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline-39.9 ± 39.63-20.1 ± 27.28
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = <0.0001 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.) · Least-square means difference: -20.8 · 95% CI -30.2 to -11.2Treatment as a fixed effect and baseline of the variable predicted as a covariate
SecondaryTime Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline

The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and specified timeframes until 24 hours. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -112032 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31968 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS.

Time frame:
baseline (pre-dose), 24 hours post-dose (1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, 2 hours, 2½ hours, 3 hours, 3½ hours, 4 hours, 4½ hours, 5 hours, 5½ hours, and 6 hours after the first dose, hourly from 7-24 hours)
Reported as:
Mean · units on a scale
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline-472.2 ± 521.89-355.2 ± 432.04
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0393 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.) · Least-square means difference: -137.6 · 95% CI -268.5 to -6.8Treatment as a fixed effect and baseline of the variable predicted as a covariate
SecondaryChange From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8

Tonsillo-Pharyngitis Assessment, or TPA, is an index of seven clinical features of the pain-producing condition itself, pharyngeal inflammation. The clinical features concern temperature, oropharyngeal color, size of tonsils, number of enanthems, largest size of cervical lymph node, number of lymph nodes, and maximum tenderness of lymph nodes. Each variable was rated on a scale of 0-3, with 0 representing the normal value, and 3 representing severe inflammation. The seven values are added together to create the TPA, ranging from 0-21. Negative change values represent improvement of symptoms.

Time frame:
Baseline (pre-dose), 24 hours post-dose
Reported as:
Mean · units on a scale
Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8-1.2 ± 2.61-2.0 ± 2.71
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = 0.0459 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.)
SecondaryPractitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose

P.A.I.N is a four step scale in which physicians rate the severity of pharyngeal inflammation: No inflammation, mild, moderate and severe inflammation.

Time frame:
24 hours post-dose
Reported as:
Number · participants
Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose
participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
No inflammation01
Mild inflammation4842
Moderate inflammation4250
Severe inflammation117
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = 0.8383 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.)
SecondaryInvestigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose

Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: "Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.

Time frame:
24 hours
Reported as:
Number · percentage of participants
Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Poor15.838.0
Fair34.728.0
Good19.818.0
Very Good13.913.0
Excellent15.83.0
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = 0.0005 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.)
SecondaryParticipant Satisfaction Scores 24 Hours After Initial Dose

After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied.

Time frame:
24 hours
Reported as:
Number · percentage of participants
Participant Satisfaction Scores 24 Hours After Initial Dose
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Extremely dissatisfied5.010.0
Very dissatisfied6.920.0
Dissatisfied11.914.0
Somewhat satisfied29.728.0
Satisfied20.817.0
Very satisfied23.89.0
Extremely satisfied2.02.0
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = 0.0005 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.)
SecondaryInvestigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7)

Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of the study by answering the following question: "Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.

Time frame:
Day 7
Reported as:
Number · percentage of participants
Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7)
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Poor11.831.6
Fair28.034.7
Good30.114.7
Very Good17.214.7
Excellent12.94.2
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = 0.0002 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.)
SecondaryTime Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe

STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -116196 (no pain at any post-dose time (0) - average baseline) to 27804 (maximum possible pain (100) - average baseline). Participants with their last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation.

Time frame:
baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)
Reported as:
Mean · units on a scale
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe-451.4 ± 491.05-283.4 ± 378.06
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0435 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.) · Least-square means difference: -156.3 · 95% CI -307.9 to -4.6
SecondarySore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose

Participants used a 6-category relief scale (no relief to complete relief) to grade the relief of his/her throat pain. The patient was instructed to swallow and: "Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now."

Time frame:
2 hours
Reported as:
Number · percentage of participants
Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
No relief18.645.1
Slight relief23.524.5
Mild relief23.511.8
Moderate relief20.613.7
Considerable relief13.74.9
Complete relief00
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = <.0001 (The a priori threshold for statistical significance is 0.05. Closed-sequential approach to control type I error: analyses through secondary outcomes #2-13 in the order listed will proceed until a p-value \>0.05 occurs.)
SecondaryTime Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05

Data reported in summary form in Primary Outcome #1 are reported here at each post-dose timepoint until the comparison resulted in a P-value \<=0.05 between the two treatment arms. STPIS was used to measure sore throat pain intensity using a 100-mm visual analog scale completed by participants that measures "pain on swallowing" (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. The full range of the scale varies by timepoint due to the time weighting sum of SPID. The full scale at 40 minutes post dose was -3188 (complete pain relief within 2 minutes of dosing that lasts 40 minutes) to 812 (maximum pain within 2 minutes lasting 40 minutes) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (rec

Time frame:
baseline (pre-dose), up to 23 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-23)
Reported as:
Mean · units on a scale
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Minutes post dose: 2-0.1 ± 0.26-0.2 ± 0.33
Minutes post dose: 4-0.3 ± 0.62-0.4 ± 0.69
Minutes post dose: 6-0.6 ± 1.05-0.8 ± 1.14
Minutes post dose: 8-0.9 ± 1.56-1.2 ± 1.60
Minutes post dose: 10-1.4 ± 2.10-1.6 ± 2.11
Minutes post dose: 12-1.9 ± 2.68-2.1 ± 2.59
Minutes post dose: 14-2.4 ± 3.30-2.5 ± 3.08
Minutes post dose: 16-3.0 ± 3.94-2.9 ± 3.56
Minutes post dose: 18-3.5 ± 4.56-3.3 ± 4.01
Minutes post dose: 20-4.1 ± 5.19-3.7 ± 4.47
Minutes post dose: 22-4.7 ± 5.83-4.1 ± 4.95
Minutes post dose: 24-5.2 ± 6.46-4.5 ± 5.43
Minutes post dose: 26-5.9 ± 7.12-4.9 ± 5.69
Minutes post dose: 28-6.5 ± 7.76-5.3 ± 6.37
Minutes post dose: 30-7.2 ± 8.41-5.8 ± 6.87
Minutes post dose: 32-7.9 ± 9.09-6.2 ± 7.36
Minutes post dose: 34-8.6 ± 9.77-6.6 ± 7.87
Minutes post dose: 36-9.3 ± 10.45-7.1 ± 8.37
Minutes post dose: 38-10.1 ± 11.14-7.5 ± 8.87
Minutes post dose: 40-10.8 ± 11.80-7.9 ± 9.38
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.1448 · Least-square means difference: 0.1 · 95% CI -0.0 to 0.1Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.1538 · Least-square means difference: 0.1 · 95% CI -0.0 to 0.3Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.1407 · Least-square means difference: 0.2 · 95% CI -0.1 to 0.5Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.2906 · Least-square means difference: 0.2 · 95% CI -0.2 to 0.7Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.4758 · Least-square means difference: 0.2 · 95% CI -0.4 to 0.8Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.6975 · Least-square means difference: 0.1 · 95% CI -0.6 to 0.9Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.9370 · Least-square means difference: 0.0 · 95% CI -0.8 to 0.9Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.8493 · Least-square means difference: -0.1 · 95% CI -1.1 to 0.9Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.6732 · Least-square means difference: -0.3 · 95% CI -1.4 to 0.9Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.5414 · Least-square means difference: -0.4 · 95% CI -1.8 to 0.9Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.4313 · Least-square means difference: -0.6 · 95% CI -2.1 to 0.9Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.3501 · Least-square means difference: -0.8 · 95% CI -2.4 to 0.9Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.2679 · Least-square means difference: -1.0 · 95% CI -2.8 to 0.8Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.2137 · Least-square means difference: -1.2 · 95% CI -3.2 to 0.7Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.1715 · Least-square means difference: -1.5 · 95% CI -3.6 to 0.6Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.1340 · Least-square means difference: -1.8 · 95% CI -4.1 to 0.5Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.1030 · Least-square means difference: -2.0 · 95% CI -4.5 to 0.4Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0788 · Least-square means difference: -2.4 · 95% CI -5.0 to 0.3Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0620 · Least-square means difference: -2.7 · 95% CI -5.5 to 0.1Baseline STPIS fitted as a covariate
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0476 · Least-square means difference: -3.0 · 95% CI -6.0 to -0.0Baseline STPIS fitted as a covariate
SecondaryKaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement

As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. An alternative definition of STPIS time to onset of relief was the time from initial dose to the time the participant reaching DIL for at least 30 minutes. Data were censored if DIL was not achieved by 120 minutes following initial dose. Definite improvement must also occur prior to re-dosing or using rescue medication.

Time frame:
2 hours
Reported as:
Median · minutes
Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement
minutesFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite ImprovementNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Log Rank · p = 0.0273
SecondaryKaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL)

As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. The time of first achieving DIL for 30 minutes within 6 hours (or until rescue or re-dosing) post-dosing will be determined. And the time falling below DIL within 6 hours will be determined. Duration is then defined as the time from first DIL until falling below DIL. Duration was set to zero if the STPIS score does not reach the DIL for at least 30 minutes for STPIS during the 6 hours.

Time frame:
6 hours
Reported as:
Mean · minutes
Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL)
minutesFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL)75.2 ± 102.4129.4 ± 65.06
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = 0.0098

Adverse events

Collected over Initial dose up to Day 7. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Flurbiprofen 8.75 mg Lozenge—0/102 (0%)36/102 (35.3%)
Placebo Lozenge—0/102 (0%)33/102 (32.4%)
Most frequent other events
Showing 10 of 54
Most frequent other events
EventFlurbiprofen 8.75 mg LozengePlacebo Lozenge
HeadacheNervous system disorders3/1026/102
NauseaGastrointestinal disorders2/1025/102
TonsillitisInfections and infestations4/1023/102
ParaesthesiaNervous system disorders4/1020/102
Abdominal pain upperGastrointestinal disorders3/1020/102
Aphthous stomatitisGastrointestinal disorders3/1022/102
Oral painGastrointestinal disorders3/1020/102
PainGeneral disorders0/1023/102
Otitis mediaInfections and infestations3/1020/102
Throat irritationRespiratory, thoracic and mediastinal disorders3/1020/102

Baseline characteristics

Age, Continuous
Age, Continuous(years)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean19.8 ± 1.4819.8 ± 1.4719.8 ± 1.47
Sex: Female, Male
Sex: Female, Male(Participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Female5463117
Male483987
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Hispanic or Latino6511
Not Hispanic or Latino9697193
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Asian314
Native Hawaiian or Other Pacific Islander011
Black or African527
White9295187
Multi-racial011
Other, not specified224
Sore Throat Pain Intensity Scale (STPIS)
Sore Throat Pain Intensity Scale (STPIS)(units on a scale)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean78.8 ± 8.5680.5 ± 7.9279.7 ± 8.27
Difficulty Swallowing Scale (DSS)
Difficulty Swallowing Scale (DSS)(units on a scale)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean76.9 ± 12.4176.3 ± 11.0476.6 ± 11.72
Swollen Throat Scale (SwoTS)
Swollen Throat Scale (SwoTS)(units on a scale)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean76.6 ± 13.9879.0 ± 12.0577.8 ± 13.07
08

Study locations

1 site
  • University of Connecticut, Student Health Services
    Storrs, Connecticut 06268, United States
09

References and documents

Publications

  • Schachtel BP, McCormick CG and Giefer EE. Patient-reported outcomes (PRO's) in the pharyngitis pain model. Abstract presented at the International Association for the Study of Pain (IASP) Scientific Conference, Montreal, Canada. 2009
  • Schachtel BP, Aspley S, Sternberg M, Berry P, Muir N, Sanner K, Rezuke J, Savino L, Shephard A, Shea T, Schachtel E. Onset of demulcent and analgesic activity of flurbiprofen lozenge. Int J Clin Pharm 2012;34:143-258.
  • Aspley S, Schachtel B, Berry P, Shephard A, Sanner K, Shea T, Smith G. The Chief Complaint: evidence of its use as an endpoint in a clinical trial. Journal of Pain 2012;13(4)Supplement:S4.
  • Aspley S, Schachtel B, Berry P, Shephard A, Sanner K, Savino L, Rezuke J, Shea T, Smith G. Treatment of odynophagia and dysphagia by flurbiprofen 8.75 mg lozenges. Pain Research & Management 2012;17(3):203.
  • Schachtel B, Aspley S, Berry P, Shephard A, Shea T,Sanner K, Smith G,Schachtel E. Efficacy of flurbiprofen 8.75mg lozenges in patients with swollen/inflamed sore throat. Abstract presented at the 14th World Congress on Pain, 27 - 31 August 2012, Milan.
  • Schachtel B, Aspley S, Berry P, Smith G, Shephard A, Shea T, Schachtel E. A patient-centered method for determining onset of action. Clinical Pharmacology in Drug Development 2012;1(4):194-195.
  • Schachtel B, Aspley S, Berry P, Shephard A, Shea T, Smith G, Sanner K, Savino L, Rezuke J, Schachtel E. Efficacy and duration of flurbiprofen 8.75 mg lozenge. Clinical Pharmacology in Drug Development 2012;1(4):194.
  • Schachtel B, Aspley S, Berry P, Shephard A, Shea T, Smith G, Schachtel E. A new cough model: de-hawthornizing a clinical trial. Clinical Pharmacology in Drug Development 2012;1(4):195.
  • Schachtel B, Aspley S, Berry P, Shephard A, Sanner K, Shea T, Smith G, Schachtel E. Chief Complaint: the therapeutogenic stimulus as the primary, individualized endpoint in clinical trials. Journal of Pain 2012;13(4)Supplement:S6.
  • Aspley S, Schachtel B, Berry P, Shephard A, Shea T, Smith G, Schachtel E. Flurbiprofen lozenges in patients with a "bad sore throat". Journal of Pain 2013;14(4):S59.
  • Schachtel B, Aspley S, Berry P, Shephard A, Shea T, Smith G, Schachtel E. The "Definite Improvement Level" (DIL) as a determinant of drug efficacy. Journal of Pain 2013;14(4):S5.
  • Shephard A, Smith G, Aspley S, Schachtel B. Efficacy of flurbiprofen 8.75 mg lozenges for streptococcal and non-streptococcal sore throat: pooled analysis of two randomised, placebo-controlled studies. Abstract presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27 - 30 April 2013, Berlin.
  • Shephard A, Smith G, Aspley S, Schachtel B. Symptomatic relief in streptococcal and non-streptococcal sore throat patients: pooled analysis of two randomised, placebo-controlled studies. Abstract presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27-30 April 2013, Berlin.
  • Aspley S, Shephard A, Schachtel E, Sanner K, Savino L, Schachtel B. Efficacy of flurbiprofen 8.75 mg lozenge in patients with a swollen and inflamed sore throat. Curr Med Res Opin. 2016 Sep;32(9):1529-38. doi: 10.1080/03007995.2016.1187119. Epub 2016 May 18. PubMed 27146963 ↗
  • Shephard A, Smith G, Aspley S, Schachtel BP. Randomised, double-blind, placebo-controlled studies on flurbiprofen 8.75 mg lozenges in patients with/without group A or C streptococcal throat infection, with an assessment of clinicians' prediction of 'strep throat'. Int J Clin Pract. 2015 Jan;69(1):59-71. doi: 10.1111/ijcp.12536. Epub 2014 Oct 9. PubMed 25296661 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2010
First posted
Jan 14, 2010
Start
Nov 2009
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Sep 21, 2017
Last update
Sep 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01049334
Responsible party
Sponsor
First posted
Jan 14, 2010
Start date
Nov 2009
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Sep 21, 2017
Last update
Sep 21, 2017

Study contacts

Timothy J Shea, BS
study director · Reckitt Benckiser Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flurbiprofen

Start the discussion